amicus
therapeutics
announces
third
quarter
financial
results
corporate
updates
galafold
revenue
million
achieve
revenue
guidance
phase
propel
study
readout
rolling
bla
submission
begin
positive
batten
disease
gene
therapy
data
presented
october
fabry
disease
gene
therapy
clinical
candidate
selected
conference
call
webcast
today
et
cranbury
globe
newswire
amicus
therapeutics
nasdaq
fold
global
biotechnology
company
focused
discovering
developing
delivering
novel
medicines
rare
diseases
today
announced
financial
results
third
quarter
ended
september
company
also
summarized
recent
program
updates
reiterated
guidance
john
crowley
chairman
chief
executive
officer
amicus
therapeutics
stated
third
quarter
made
tremendous
progress
advancing
mission
patients
track
achieve
key
strategic
priorities
including
global
fabry
commercial
launch
pompe
development
program
advancing
gene
therapy
pipeline
efforts
remain
strongly
positioned
achieve
vision
delivering
groundbreaking
new
medicines
hopefully
one
day
cures
people
living
rare
corporate
highlights
global
revenue
galafold
migalastat
third
quarter
third
quarter
revenue
represented
increase
total
revenue
million
third
quarter
constant
currency
basis
third
quarter
total
revenue
million
representing
operational
revenue
growth
measured
constant
currency
exchange
rates
benefited
positive
currency
impact
million
galafold
performance
driven
largely
strong
patient
demand
global
compliance
adherence
rates
continue
exceed
third
quarter
revenue
represented
increase
total
revenue
million
third
quarter
constant
currency
basis
third
quarter
total
revenue
million
representing
operational
revenue
growth
measured
constant
currency
exchange
rates
benefited
positive
currency
impact
million
galafold
performance
driven
largely
strong
patient
demand
global
compliance
adherence
rates
continue
exceed
global
phase
propel
clinical
study
pompe
disease
lopd
track
data
date
planned
infusions
assessments
ongoing
propel
study
completed
schedule
company
plans
initiate
rolling
bla
fourth
quarter
completing
final
submission
first
half
date
planned
infusions
assessments
ongoing
propel
study
completed
schedule
company
plans
initiate
rolling
bla
fourth
quarter
completing
final
submission
first
half
highlighted
today
call
new
natural
history
data
amicus
chart
review
study
people
living
lopd
treated
current
standard
care
alglucosidase
alfa
data
consistent
medical
literature
supports
propel
design
assumptions
data
consistent
medical
literature
supports
propel
design
assumptions
additional
phase
data
presented
child
neurology
society
annual
meeting
october
data
shows
meaningful
effect
slowing
disease
progression
months
compared
natural
history
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
initial
data
phase
study
expected
early
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
gene
therapy
clinical
candidate
selected
ind
enabling
studies
fabry
disease
initial
data
company
aav
gene
therapy
engineered
gla
transgene
demonstrated
significantly
better
reduction
one
gla
full
set
preclinical
data
presented
medical
conference
early
initial
data
company
aav
gene
therapy
engineered
gla
transgene
demonstrated
significantly
better
reduction
one
gla
full
set
preclinical
data
presented
medical
conference
early
cash
position
sufficient
achieve
without
need
future
dilutive
financings
company
continues
carefully
manage
expenses
investments
executing
galafold
launch
advancing
development
programs
third
quarter
financial
results
total
revenue
third
quarter
million
increase
total
revenue
million
third
quarter
constant
currency
basis
third
quarter
total
revenue
million
representing
operational
revenue
growth
measured
constant
currency
exchange
rates
reported
revenue
aided
positive
currency
impact
million
cash
cash
equivalents
marketable
securities
totaled
million
september
compared
million
december
total
gaap
operating
expenses
million
third
quarter
increased
compared
million
third
quarter
reflecting
continued
investments
pipeline
offset
decreased
travel
costs
total
operating
expenses
million
third
quarter
increased
compared
million
third
quarter
reflecting
continued
investments
pipeline
offset
decreased
travel
costs
net
loss
million
per
share
compared
net
loss
million
per
share
third
quarter
third
quarter
net
loss
included
impact
million
relating
extinguishment
debt
full
reconciliation
gaap
results
company
adjusted
measures
reporting
periods
appear
tables
press
release
financial
guidance
company
anticipates
total
galafold
revenue
million
million
based
average
exchange
rates
operating
expense
guidance
million
million
driven
continued
investment
global
galafold
launch
clinical
studies
advancing
gene
therapy
pipeline
cash
cash
equivalents
marketable
securities
totaled
million
september
based
current
operating
models
company
believes
current
cash
position
along
net
proceeds
senior
secured
term
loan
expected
future
revenues
sufficient
fund
company
operations
ongoing
research
programs
reconciliation
differences
expectation
corresponding
gaap
measure
available
without
unreasonable
effort
due
high
variability
complexity
low
visibility
items
would
excluded
gaap
measure
anticipated
milestones
program
galafold
migalastat
oral
precision
medicine
fabry
disease
track
meet
revenue
guidance
range
million
million
continued
geographic
expansion
registry
phase
studies
underway
pompe
disease
plans
initiate
rolling
biologics
license
application
bla
addition
complete
clinical
results
propel
support
full
approval
additional
supportive
studies
including
study
living
pompe
gene
therapy
portfolio
advance
regulatory
discussions
finalize
clinical
regulatory
path
batten
disease
gene
therapy
development
program
initial
data
batten
disease
phase
study
expected
early
advance
regulatory
discussions
finalize
clinical
regulatory
path
continue
toxicology
work
pompe
disease
progress
towards
ind
additional
preclinical
data
expected
across
multiple
programs
manufacturing
advancements
across
portfolio
conference
call
webcast
amicus
therapeutics
host
conference
call
audio
webcast
today
november
et
discuss
third
quarter
financial
results
corporate
updates
interested
participants
investors
may
access
conference
call
dialing
canada
international
conference
id
live
audio
webcast
related
presentation
materials
also
accessed
via
investors
section
amicus
therapeutics
corporate
website
web
participants
encouraged
register
website
minutes
prior
start
call
replay
call
available
seven
days
beginning
et
november
access
numbers
replay
canada
international
conference
id
galafold
migalastat
mg
capsules
oral
pharmacological
chaperone
treatment
fabry
disease
adults
amenable
gla
variants
patients
galafold
works
stabilizing
body
dysfunctional
enzyme
clear
accumulation
disease
substrate
globally
amicus
therapeutics
estimates
approximately
percent
fabry
patients
may
amenable
gla
variants
though
amenability
rates
within
range
vary
geography
galafold
approved
countries
around
world
including
eu
japan
others
indications
usage
galafold
indicated
treatment
adults
confirmed
diagnosis
fabry
disease
amenable
galactosidase
alpha
gene
gla
variant
based
vitro
assay
data
indication
approved
accelerated
approval
based
reduction
kidney
interstitial
capillary
cell
globotriaosylceramide
kic
substrate
continued
approval
indication
may
contingent
upon
verification
description
clinical
benefit
confirmatory
trials
important
safety
information
adverse
reactions
common
adverse
reactions
reported
galafold
headache
nasopharyngitis
urinary
tract
infection
nausea
pyrexia
use
specific
populations
insufficient
clinical
data
galafold
use
pregnant
women
inform
risk
major
birth
defects
miscarriage
advise
women
potential
risk
fetus
known
galafold
present
human
milk
therefore
developmental
health
benefits
breastfeeding
considered
along
mother
clinical
need
galafold
potential
adverse
effects
breastfed
child
galafold
underlying
maternal
condition
galafold
recommended
use
patients
severe
renal
impairment
renal
disease
requiring
dialysis
safety
effectiveness
galafold
established
pediatric
patients
report
suspected
adverse
reactions
contact
amicus
therapeutics
fda
medwatch
additional
information
galafold
including
full
prescribing
information
please
visit
https
pi
eu
important
safety
information
treatment
galafold
initiated
supervised
specialists
experienced
diagnosis
treatment
fabry
disease
galafold
recommended
use
patients
nonamenable
mutation
galafold
intended
concomitant
use
enzyme
replacement
therapy
galafold
recommended
use
patients
fabry
disease
severe
renal
impairment
ml
min
safety
efficacy
galafold
children
years
age
yet
established
safety
efficacy
galafold
children
years
age
yet
established
dosage
adjustments
required
patients
hepatic
impairment
elderly
population
limited
experience
use
medicine
pregnant
women
pregnant
think
may
pregnant
planning
baby
take
medicine
checked
doctor
pharmacist
nurse
taking
galafold
effective
birth
control
used
known
whether
galafold
excreted
human
milk
contraindications
galafold
include
hypersensitivity
active
substance
excipients
listed
prescribing
information
advised
periodically
monitor
renal
function
echocardiographic
parameters
biochemical
markers
every
months
patients
initiated
galafold
switched
galafold
overdose
general
medical
care
recommended
case
galafold
overdose
common
adverse
reaction
reported
headache
experienced
approximately
patients
received
galafold
complete
list
adverse
reactions
please
review
summary
product
characteristics
call
doctor
medical
advice
side
effects
important
safety
information
galafold
including
posology
method
administration
special
warnings
drug
interactions
adverse
drug
reactions
please
see
european
smpc
galafold
available
ema
website
amicus
therapeutics
amicus
therapeutics
nasdaq
fold
global
biotechnology
company
focused
discovering
developing
delivering
novel
medicines
people
living
rare
metabolic
diseases
extraordinary
patient
focus
amicus
therapeutics
committed
advancing
expanding
robust
pipeline
medicines
rare
metabolic
diseases
information
please
visit
company
website
follow
twitter
linkedin
financial
measures
addition
financial
information
prepared
accordance
gaap
press
release
also
contains
adjusted
financial
measures
believe
provide
investors
management
supplemental
information
relating
operating
performance
trends
facilitate
comparisons
periods
respect
projected
information
adjusted
financial
measures
measures
considered
addition
substitute
information
prepared
accordance
gaap
typically
exclude
certain
gaap
items
management
believe
affect
basic
operations
meet
gaap
definition
unusual
items
companies
may
define
measures
different
ways
full
reconciliations
gaap
results
comparable
measures
reported
periods
appear
financial
tables
section
press
release
provide
expectation
operating
expenses
basis
reconciliation
differences
expectation
corresponding
gaap
measure
generally
available
without
unreasonable
effort
due
potentially
high
variability
complexity
low
visibility
items
would
excluded
gaap
measure
relevant
future
period
unusual
gains
losses
variability
excluded
items
may
significant
potentially
unpredictable
impact
future
gaap
results
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
relating
preclinical
clinical
development
product
candidates
timing
reporting
results
preclinical
studies
clinical
trials
prospects
timing
potential
regulatory
approval
product
candidates
commercialization
plans
manufacturing
supply
plans
financing
plans
projected
revenues
cash
position
company
inclusion
statements
regarded
representation
us
plans
achieved
statements
press
release
may
turn
wrong
affected
inaccurate
assumptions
might
make
known
unknown
risks
uncertainties
example
respect
statements
regarding
goals
progress
timing
outcomes
discussions
regulatory
authorities
particular
potential
goals
progress
timing
results
preclinical
studies
clinical
trials
including
impacted
related
disruption
based
current
information
potential
impact
operations
pandemic
inherently
unknown
predicted
confidence
may
cause
actual
results
performance
differ
materially
statements
release
including
without
limitation
impact
general
political
economic
conditions
including
result
efforts
governmental
authorities
mitigate
travel
bans
shelter
place
orders
business
closures
resource
allocations
manufacturing
supply
chain
disruptions
limitations
patient
access
commercial
clinical
product
addition
impact
pandemic
actual
results
may
differ
materially
set
forth
release
due
risks
uncertainties
inherent
business
including
without
limitation
potential
results
clinical
preclinical
studies
indicate
product
candidates
unsafe
ineffective
potential
may
difficult
enroll
patients
clinical
trials
potential
regulatory
authorities
including
fda
ema
pmda
may
grant
may
delay
approval
product
candidates
potential
may
successful
commercializing
galafold
europe
japan
us
geographies
product
candidates
approved
potential
preclinical
clinical
studies
could
delayed
identify
serious
side
effects
safety
issues
potential
may
able
manufacture
supply
sufficient
clinical
commercial
products
potential
need
additional
funding
complete
studies
manufacturing
results
earlier
preclinical
studies
clinical
trials
may
predictive
future
results
statements
regarding
corporate
financial
guidance
financial
goals
attainment
goals
respect
statements
regarding
projections
company
revenue
cash
position
actual
results
may
differ
based
market
factors
company
ability
execute
operational
budget
plans
addition
statements
subject
risks
detailed
annual
report
form
year
ended
december
quarterly
report
filed
form
quarter
ended
june
quarterly
report
filed
form
filed
today
cautioned
place
undue
reliance
statements
speak
date
hereof
statements
qualified
entirety
cautionary
statement
undertake
obligation
revise
update
news
release
reflect
events
circumstances
date
hereof
contacts
investors
amicus
therapeutics
andrew
faughnan
director
investor
relations
afaughnan
media
amicus
therapeutics
diana
moore
head
global
corporate
communications
dmoore
table
amicus
therapeutics
consolidated
statements
operations
unaudited
thousands
except
share
per
share
amounts
three
months
ended
september
nine
months
ended
september
net
product
sales
cost
goods
sold
gross
profit
operating
expenses
research
development
selling
general
administrative
changes
fair
value
contingent
consideration
payable
depreciation
amortization
total
operating
expenses
loss
operations
income
expense
interest
income
interest
expense
loss
exchange
convertible
notes
loss
extinguishment
debt
income
expense
loss
income
tax
income
tax
expense
benefit
net
loss
attributable
common
stockholders
net
loss
attributable
common
stockholders
per
common
share
basic
diluted
common
shares
outstanding
basic
diluted
table
amicus
therapeutics
consolidated
balance
sheets
unaudited
thousands
except
share
per
share
amounts
september
december
assets
current
assets
cash
cash
equivalents
investments
marketable
securities
accounts
receivable
inventories
prepaid
expenses
current
assets
total
current
assets
operating
lease
assets
less
accumulated
amortization
september
december
respectively
property
equipment
less
accumulated
depreciation
september
december
respectively
research
development
goodwill
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
liabilities
operating
lease
liabilities
total
current
liabilities
deferred
reimbursements
debt
contingent
consideration
payable
deferred
income
taxes
operating
lease
liabilities
liabilities
total
liabilities
commitments
contingencies
stockholders
equity
common
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
additional
capital
accumulated
comprehensive
loss
foreign
currency
translation
adjustment
unrealized
loss
gain
securities
warrants
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
table
amicus
therapeutics
reconciliation
financial
measures
thousands
